Browse

Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia

DC Field Value Language
dc.contributor.authorKim, Sung-Han-
dc.contributor.authorKim, Kye-Hyung-
dc.contributor.authorKim, Hong-Bin-
dc.contributor.authorKim, Nam-Joong-
dc.contributor.authorKim, Eui-Chong-
dc.contributor.authorOh, Myoung-don-
dc.contributor.authorChoe, Kang-Won-
dc.date.accessioned2010-01-27T06:57:34Z-
dc.date.available2010-01-27T06:57:34Z-
dc.date.issued2007-11-07-
dc.identifier.citationAntimicrob Agents Chemother. 2008 Jan;52(1):192-7. Epub 2007 Nov 5.en
dc.identifier.issn0066-4804 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17984229-
dc.identifier.urihttp://aac.asm.org/cgi/reprint/52/1/192.pdf-
dc.identifier.urihttp://hdl.handle.net/10371/45514-
dc.description.abstractLimited data on the clinical outcome of vancomycin treatment compared with that of beta-lactam treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia (MSSA-B) are available. We used different and complementary approaches: (i) a retrospective cohort study using a propensity score to adjust for confounding by treatment assignment and (ii) a matched case-control study. Of all patients with S. aureus bacteremia (SAB) in two university-affiliated hospitals over a 7-year period, 294 patients with MSSA-B were enrolled in the cohort study. The cases for the case-control study were defined as patients who received vancomycin treatment for MSSA-B; the controls, who were patients that received beta-lactam treatment for MSSA-B, were selected at a 1:2 (case:control) ratio according to the objective matching scoring system and the propensity score system. In the cohort study, SAB-related mortality in patients with vancomycin treatment (37%, 10/27) was significantly higher than that in those with beta-lactam treatment (18%, 47/267) (P = 0.02). In addition, multivariate analysis revealed that vancomycin treatment was associated with SAB-related mortality when independent predictors for SAB-related mortality and propensity score were considered (adjusted odds ratio of 3.3, 95% confidence interval of 1.2 to 9.5). In the case-control study using the objective matching scoring system and the propensity score system, SAB-related mortality in case patients was 37% (10/27) and in control patients 11% (6/54) (P < 0.01). Our data suggest that vancomycin is inferior to beta-lactam in the treatment of MSSA-B.en
dc.language.isoenen
dc.publisherAmerican Society for Microbiologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAnti-Bacterial Agents/*pharmacology/*therapeutic useen
dc.subjectBacteremia/*drug therapy/microbiology/mortalityen
dc.subjectCase-Control Studiesen
dc.subjectCohort Studiesen
dc.subjectFemaleen
dc.subjectHospitals, Universityen
dc.subjectHumansen
dc.subjectKoreaen
dc.subjectMaleen
dc.subjectMethicillin/*pharmacology/therapeutic useen
dc.subjectMicrobial Sensitivity Testsen
dc.subjectMiddle Ageden
dc.subjectStaphylococcal Infections/drug therapy/microbiology/mortalityen
dc.subjectStaphylococcus aureus/*drug effectsen
dc.subjectTreatment Outcomeen
dc.subjectVancomycin/*therapeutic useen
dc.subjectbeta-Lactams/pharmacology/therapeutic useen
dc.titleOutcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremiaen
dc.typeArticleen
dc.contributor.AlternativeAuthor김성한-
dc.contributor.AlternativeAuthor김계형-
dc.contributor.AlternativeAuthor김홍빈-
dc.contributor.AlternativeAuthor김남중-
dc.contributor.AlternativeAuthor김의종-
dc.contributor.AlternativeAuthor오명돈-
dc.contributor.AlternativeAuthor최강원-
dc.identifier.doi10.1128/AAC.00700-07-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse